These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 22146410)

  • 1. The REFLEX study: a missed opportunity?
    Giovannoni G
    Lancet Neurol; 2012 Jan; 11(1):22-4. PubMed ID: 22146410
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial.
    Comi G; De Stefano N; Freedman MS; Barkhof F; Polman CH; Uitdehaag BM; Casset-Semanaz F; Hennessy B; Moraga MS; Rocak S; Stubinski B; Kappos L
    Lancet Neurol; 2012 Jan; 11(1):33-41. PubMed ID: 22146409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Interferon therapy of multiple sclerosis. A question of the correct dose?].
    Hohlfeld R
    Nervenarzt; 2001 Feb; 72(2):67-8. PubMed ID: 11256156
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluation of magnetic resonance imaging sensitivity in patients with relapsing remitting multiple sclerosis: baseline versus Betaseron treatment trials.
    Frank JA; Bash C; Stone L; Petrella J; Maloni H; McFarland H
    Acad Radiol; 1996 Aug; 3 Suppl 2():S173-5. PubMed ID: 8796554
    [No Abstract]   [Full Text] [Related]  

  • 5. Treat early, but treat hard: Interferon-beta dose makes a difference.
    Mikol DD
    J Neuroophthalmol; 2001 Dec; 21(4):237-9. PubMed ID: 11756850
    [No Abstract]   [Full Text] [Related]  

  • 6. Introduction.
    Owens GM
    J Manag Care Pharm; 2013; 19(1 Suppl A):S3. PubMed ID: 23383727
    [No Abstract]   [Full Text] [Related]  

  • 7. Optimizing immunomodulatory therapy for MS patients: an integrated management model.
    Jeffery D; Bashir K; Buchwald L; Coyle P; Freedman M; Markowitz C; Rammohan K; Reder T; Sharief M; Wolinsky J
    J Neurol Sci; 2002 Sep; 201(1-2):89-90. PubMed ID: 12163200
    [No Abstract]   [Full Text] [Related]  

  • 8. Intramuscular interferon beta-1a and evolving treatment options and outcomes measurement for MS: considerations for managed care.
    Barnes CJ; Caon C; Foley JF; Friedman M; Menzin J; Nair KV; Nichols C; Olvey EL; Owens GM; Pill MW; Skrepnek GH; White LA; Zerkowski K
    J Manag Care Pharm; 2013; 19(1 Suppl A):S1-53. PubMed ID: 23383730
    [No Abstract]   [Full Text] [Related]  

  • 9. The effects of interferon beta-1a on proton MR spectroscopic imaging in patients with multiple sclerosis, a controlled study, preliminary results.
    Toprak MK; Cakir B; Ulu EM; Arat Z; Benli US; Can U; Ağildere M
    Int J Neurosci; 2008 Dec; 118(12):1645-58. PubMed ID: 18937112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacological and clinical profile of IFNbeta-1a (Avonex IM Injection Syringe 30 microg].
    Sumino R
    Nihon Yakurigaku Zasshi; 2007 Mar; 129(3):209-17. PubMed ID: 17379973
    [No Abstract]   [Full Text] [Related]  

  • 11. [Clinical efficacy and safety of long-term immunomodulating therapy with interferon beta].
    Demina TL; Khachanova NV; Davydovskaia MV; Popova NF; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(4):24-6. PubMed ID: 18567192
    [No Abstract]   [Full Text] [Related]  

  • 12. Local pain during REBIF injection is not due to acidic pH.
    Buttmann M; Goebeler M; Rieckmann P
    J Neurol Neurosurg Psychiatry; 2004 Jul; 75(7):1078. PubMed ID: 15201384
    [No Abstract]   [Full Text] [Related]  

  • 13. [A comparative analysis of rebif 22-mcg and copaxone efficacy in multiple sclerosis].
    Zavalishin IA; Peresedova AV; Stoĭda NI; Rebrova Oi; Zakharova MN; Adarcheva LS; Niazbekova AS; Askarova LSh; Baĭdina EV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006; Spec No 3():111-5. PubMed ID: 17172245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of multiple sclerosis].
    Midgard R
    Tidsskr Nor Laegeforen; 2001 Aug; 121(19):2254. PubMed ID: 11571873
    [No Abstract]   [Full Text] [Related]  

  • 15. Interferon beta-1a and beta-1b for treatment of multiple sclerosis.
    Benatar M
    Lancet; 2002 Nov; 360(9343):1428; author reply 1428-9. PubMed ID: 12424021
    [No Abstract]   [Full Text] [Related]  

  • 16. [Interferon beta treatment of disseminated sclerosis in Denmark--current status].
    Sørensen PS
    Ugeskr Laeger; 2000 Nov; 162(45):6091-3. PubMed ID: 11107953
    [No Abstract]   [Full Text] [Related]  

  • 17. [10 years of interferon treatment in multiple sclerosis. Does the future belong to high-dose therapy?].
    MMW Fortschr Med; 2003 May; 145 Suppl 2():108. PubMed ID: 14579501
    [No Abstract]   [Full Text] [Related]  

  • 18. [About the article: "Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis" by Jacobs LD et al].
    Labetouelle M
    J Fr Ophtalmol; 2001 Feb; 24(2):222. PubMed ID: 11332406
    [No Abstract]   [Full Text] [Related]  

  • 19. [High doses of interferon in the treatment of multiple sclerosis].
    Muñoz D
    Rev Neurol; 2001 May 1-15; 32(9):899. PubMed ID: 11424041
    [No Abstract]   [Full Text] [Related]  

  • 20. Subcutaneous interferon Beta-1a in pediatric multiple sclerosis: a retrospective study.
    Tenembaum SN; Banwell B; Pohl D; Krupp LB; Boyko A; Meinel M; Lehr L; Rocak S; Cantogno EV; Moraga MS; Ghezzi A;
    J Child Neurol; 2013 Jul; 28(7):849-56. PubMed ID: 23666046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.